• Beam Therapeutics Inc BEAM.OQ reported a quarterly adjusted loss of $1.09​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $1.73. The mean expectation of sixteen analysts for the quarter was for a loss of $1.20 per share. Wall Street expected results to range from $-1.53 to -88 cents per share.

• Revenue fell 90.5% to $30.07 million from a year ago; analysts expected $16.93 million.

• Beam Therapeutics Inc's reported EPS for the quarter was a loss of $1.09​.

• The company reported a quarterly loss of $90.35 million.

• Beam Therapeutics Inc shares had risen by 24.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $42.00

This summary was machine generated from LSEG data February 25 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)